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2 Main text 
Word count: 1,131 (original draft: 976) 
Type 2 diabetes affects 8% of adults worldwide,1 leading to 15% excess mortality2 and 67% 
excess disabilities.3 In 2017, people with diabetes accounted for 24% of all US healthcare 
spending:  diabetes-attributable costs were $327 billion, comprising $237 billion in direct 
healthcare costs, equivalent to $9601 per person, plus $90 bn in losses of productivity. Costs 
rise with age, steeply above 45 years, reflecting the large contribution from type 2 diabetes. 4  
In the UK, diabetes accounts for approximately 10% of total National Health Service (NHS) 
budget,5 with direct costs of £2564 per patient per year at 2010-11 prices (accounting for 
inflation, £2801 per year in 2016-17).6 Type 2 diabetes is being diagnosed at younger ages, 
with more complications, as populations become more overweight, and costs are rising rapidly 
with increasing prevalence and new, more expensive treatments. Management focuses 
heavily on pharmacotherapy, but morbidity and mortality remain high.7 Bariatric surgery, with 
its own complications, can induce remission of type 2 diabetes but reaches only 1% of the 
eligible population, so periods of remission through primary care-based interventions could be 
valuable.  In the DiRECT trial (ISRCTN03267836), 68 (46%) of 149 participants assigned to 
the study intervention achieved remission of type 2 diabetes after intensive weight 
management in routine primary care compared with six (4%) of 149 participants assigned to 
usual-care.7-9 We did a cost-effectiveness analysis of the Counterweight-Plus intervention 
used in DIRECT, with cost per additional diabetes remission at 1 year calculated from an 
intention to treat analysis of DIRECT and the differences in costs (UK NHS perspective, 2017 
prices) and effects between the Counterweight-Plus and usual-care groups (appendix).  
The DiRECT/Counterweight-Plus intervention involves fixed ‘set-up’ costs, for Counterweight 
specialists to train practitioners (practice nurses or dietitians who see participants), 
practitioners’ attendance time, dedicated training materials, and programme support including 
online access to a medical advisor under an annual licence fee. Resource use (table) was 
collected prospectively throughout the study for every participant, including formula diet 
sachets (as total diet replacement [soups and shakes, 825–853 kcal per day for 12-20 weeks] 
then reducing over stepped food reintroduction, plus optional daily meal-replacement sachets 
during weight loss maintenance, and for rescue packages), review appointments with a 
practitioner, and supporting workbooks costed in full for all randomly assigned intervention 
participants.7 Total cost per intervention participant of delivering the DiRECT/Counterweight-
Plus programme was £1223 (95%CI £1147-£1294); the largest cost components were 
practitioner visits (£447 per participant; 37% of total intervention cost) and formula diet sachets 
(495 sachets [£708] per participant; 58% of total intervention cost).   
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Data for routine health-care contacts and medication use were collected directly from general 
practitioner (GP) records for both groups. Antidiabetes and antihypertensive medications, 
suspended on commencing the intervention and reinstated as necessary under clinical 
guidelines, were costed from observed individual participants’ treatments. The intervention 
group had significantly lower cost per participant than did controls for antidiabetes drugs 
(mean difference £120, 95%CI 78-163), antihypertensive drugs (£14, 8-22), diabetes-related 
GP visits (£17, 8-26), and diabetes-unrelated practice nurse visits (£6, 1-11). No significant 
differences were observed for other care contacts.  
Reduced routine resource use thus provides some cost offset within the first year.  Mean 1-
year management cost per participant (intervention delivery plus routine NHS costs) (n=149 
in both groups) was £1913 (SD 1161) versus £846 (1066) for controls, thus incremental 
intervention cost was £1067(820-1322; figure). The incremental cost per additional 1-year 
remission (difference in costs, divided by difference in remissions [41·6%]) was £2564(95%CI 
£1867-£3453). 
We have not attempted to project precise costs for the DiRECT/Counterweight-Plus 
intervention under routine care conditions but, being based on observed resource use under 
trial conditions, the figures represent generous estimates. In DiRECT, 149 intervention 
participants were managed by 33 practitioners. This ratio (5:1) would be expected to be much 
greater in routine practice, where similar numbers of patients might be managed by a single 
dedicated practitioner. Such a situation would entail fewer staff undergoing training, and lower 
annual costs, though these intervention set-up costs formed a minor cost element (£48 per 
participant; table). With future research and development, seeing patients in groups rather 
than individually might also offer small cost savings. Substantially lower costs might be 
achieved if greater restrictions were placed on the number of sachets issued to each patient 
and by negotiating lower unit costs for large contracts. The within-trial costs reported here thus 
represent a conservative basis from which to estimate potential 12-month 
DiRECT/Counterweight-Plus implementation costs. At £1067 per participant, the cost was 
about half that of the intensive lifestyle intervention (2012 US$2865 per participant) in the US 
Look AHEAD trial; compared with Look AHEAD, DiRECT (shorter diabetes durations, but in a 
relatively socially deprived study population) achieved greater weight losses and an almost 
four times greater 1-year remission rate (46% vs.12%).10,11 
The medication cost savings resulted from discontinuation antidiabetes and antihypertensive 
drugs on commencing the intervention, and from the lesser likelihood of their reintroduction 
and effects on subsequent dose or number of drugs used (via a guideline-based protocol) if 
the participant lost weight. The number of prescribed antidiabetes and antihypertensive 
medications was more than halved at 12 months in the intervention group.8 Use of other 
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concomitant medications was similar across groups over the first 12 months. 8 Coupled with 
the low costs of most other medications, an aggregated difference between study groups 
seems unlikely; detailed evaluation of concomitant medications was therefore excluded from 
the present 12-month analysis. 
DiRECT is the first non-surgical study to set remission of type 2 diabetes as a primary outcome 
and is implemented entirely within primary care. The relative costs of the intervention, and of 
routine diabetes care, are similar in other studies. DiRECT participants were very typical of 
people currently living with type 2 diabetes within 6 years of diagnosis.  A high proportion were 
from socially deprived circumstances, where type 2 diabetes is most prevalent and difficult to 
manage.10 Our results are thus likely to be robust and widely transferable. However, the 
population studied was almost entirely of white European ethnic origin; evidence is needed for 
people from other racial or ethnic backgrounds in whom type 2 diabetes has different 
characteristics. 
Our immediate objective here is to report the costs of mounting an intervention with evident 
clinical benefits over the short term, potentially for a large proportion of people with type 2 
diabetes, whose current management is expensive and growing. The offsetting cost savings 
seen in the first 12 months of the trial were modest, but reduced healthcare demand might 
persist into future years after the initial intervention costs are completed. Remission is an 
incentivising target for diabetes care but 14% (5/36) did not achieve remission despite 
substantial weight loss.9 However, weight loss has many other personal, clinical and public 
health benefits. Studies using different methods suggest reduced life expectancy with type 2 
diabetes of 6-7 years in younger people, 6,12 and substantial weight loss consistently improves 
multiple cardiometabolic risk factors, potentially extending life expectancy.13,14 Our analysis 
suggests that each case of remission costs £2564 on average, as a basis for budget planning 
and providing a platform for long-term cost-effectiveness. On-going follow-up of DiRECT will 
inform modelling of long-term health gains, resource savings, and quality of life. Participants’ 
abilities to maintain weight loss and to avoid relapse of diabetes will be critical to enhance 
long-term cost-effectiveness, requiring appropriate research and development investment for 
programme improvement. However, based on this within-trial analysis, irrespective of any 
marginal efficiencies from delivering the weight-management programme in routine practice 
and the exact cost per quality-adjusted life-year gained, the case already seems strong for 
diabetes care budgets to offer the support for patients to attempt remission. 
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4 Tables and figures 
Table 1 Cost (£***) of intervention delivery and routine resource use per participant (n=149 for 
each arm) over the first 12 months of the DiRECT trial. 
  
 Cost (per participant) (SD) (£) Mean difference 
(Intervention – 
Control) (£) (95% CI§ ) 
Intervention 
(n=149*) 
Control 
(n=149*) 
1. Intervention delivery cost    
1a. Set-up cost (annualised over five years)    
Counterweight-Plus specialist training, 
support and mentoring 
14·7 (-)† 0 (-) 14·7 (-) 
Practice nurses/dieticians’ training time 33·0 (-) ‡ 0 (-) 33·0 (-) 
Total intervention set-up cost 48 (-)  48 (-) 
1b. Intervention running cost    
Practice nurse/dietician visits 447 (199)‖ 0 (-) 447 (415, 478) 
Sachets 708 (311)¶ 0 (-) 708 (659, 757) 
Counterweight-Plus booklets 20 (-) 0 (-) 20 (-) 
Total intervention running cost 1,175 (463) 0 (-) 1,175 (1,099, 1,246) 
Total intervention cost 1,223 (463) 0 (-) 1,223 (1,147, 1,294) 
    
2. Cost of routine resource use    
2a. Primary and secondary care contact    
Primary and community care visits related 
to diabetes 
   
GP 17 (31) 34 (47) -17 (-26, -7·6) 
Practice nurse 19 (15) 22 (16) -3·3 (-7·0, 0·3) 
Health care assistant 1·0 (2·6) 1·3 (2·9) -0·3 (-0·9, 0·4) 
Community care 16 (28) 18 (43) -2·2 (-11, 5·6) 
Primary and community care visits not 
related to diabetes 
   
GP 149 (179) 154 (178) -5·4 (-47, 36) 
Practice nurse 10 (17) 16 (30) -5·6 (-11, -0·8) 
Health care assistant 0·6 (1·9) 1·1 (6·2) -0·5 (-1·6, 0·4) 
Community care 13 (45) 13 (92) -0·2 (-20, 14) 
Outpatient visits 244 (476) 261 (407) -17 (-111, 83) 
Hospitalisation 187 (796) 157 (713) 30 (-142, 201) 
Total cost of primary and secondary 
care contact  
656 (1,047) 677 (1,028) -21 (-249, 215) 
 
2b. Medications 
   
Diabetics drugs 29 (86) 149 (228) -120 (-163, -78) 
Anti-hypertensive drugs 5·3 (9·1) 19 (43) -14 (-22, -7·9) 
Total cost of medications 34 (87) 168 (229) -134 (-177, -93) 
Total cost of routine resource use 691 (1,058) 846 (1,066) -155 (-394, 74) 
    
GRAND TOTAL cost per participant 1,913 (1,161) 846 (1,066) 1,067 (820, 1,322) 
* Intention to treat analysis. Included one participant in each arm who moved away from the trial participating 
practice. Their healthcare resource use was assumed to be 0 after moving, and their medication use was 
assumed to continue since moving. 
§ 95% CI for the mean differences and SD for the total costs were obtained from the 1,000 iteration bootstrap. 
† 33 practitioners were trained and supported by the Counterweight-Plus specialist team for £300 per 
practitioner. This gives a total cost of £9,900 for all the 149 participants in the intervention arm, which is equal to 
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£66·4 (=£9,900/149) per participants. Annualizing the training cost over five years using the formula, equivalent 
annual cost =K/[(1-1/(1+r)n)/r], where K=£66·4, r=3·5%, n=5, gives an annual specialist training and support cost 
of £14·7 per participant. 
‡ 33 practitioners were trained for 16 hours, at £42 per hour for their time, summing to a total practitioner training 
time cost of £22,176, which is equivalent to £149 per participant. Annualizing the training time cost over five 
years using the formula, equivalent annual cost=K/[(1-1/(1+r)n)/r], where K=£149, r=3·5%, n=5, gives an annual 
practitioner training time cost of £33·0 per participant. 
‖ Cost of practice nurse/dietician visits was calculated from the observed total duration of visits (639 min) for an 
average of 15·6 visits per participant, applying the standard unit cost of £42 per hour from the unit cost of medical 
and social care 2016/2017 from the UK Personal Social Service Research Unit. The number of visits (SD) for 
each stage of the intervention are 7·7 (2.9) for total diet replacement, 3·7 (1.9) for food reintroduction, 3·5 (2·7) 
for weight maintenance, 0·3 (0·7) for rescue package-total food replacement, and 0·4 (1·0) for rescue package-
food reintroduction. 
¶ Cost of sachets was calculated from average number of sachets consumed per participant (495), multiplied by 
the unit cost of sachets (£1·43, =20/14, £20 per 14 sachets). The average number (SD) of sachets per participant 
consumed at each stage were 383 (156) for total diet replacement, 62 (50) for food reintroduction, 30 (48) for 
weight maintenance, 10 (27) for rescue package-total food replacement and 10 (31) for rescue package-food 
reintroduction. 
***Prices in £ sterling can be converted to Dollars and other currencies using online converters 
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Figure 1 Components of one-year cost per participant: DiRECT/Counterweight-
Plus intervention vs. control.  Prices in £ sterling can be converted to Dollars and 
other currencies using online converters 
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The DiRECT trial 
The Diabetes Remission Clinical Trial (DiRECT) assesses the extent to which effective weight 
management, delivered in the primary care setting, can lead to sustained remission of type 2 diabetes.1,2 
DiRECT is an open-label, cluster-randomised trial at 49 primary care practices in Scotland and the 
Tyneside region of England. 12-month follow-up is completed, extended follow-up is ongoing. The 
geographical regions included in DiRECT represent the patient characteristics and poorer social settings 
where type 2 diabetes is most frequent. Eligibility criteria included age 20–65 years, type 2 diabetes 
diagnosed within the previous 6 years, BMI of 27–45 kg/m2, and most recent HbA1c greater than 48 
mmol/mol (6·5%) (or >43 mmol/mol [6%] if taking diabetes medication). Between July, 2014, and 
August, 2016, 298 participants were randomly assigned equally to control (usual care) and intervention 
groups. Both groups continued to receive optimal routine care under current clinical guidelines. 
Participants in the intervention group followed the Counterweight-Plus weight-management programme, 
which aims to achieve and maintain substantial weight loss, aiming for >15 kg loss. The programme, 
delivered in the primary care setting by trained dietitians or practice nurses, contains three phases: total 
diet replacement (TDR), when participants consume only a low-energy formula diet (soups and shakes 
that contained 825–853 kcal/day; 59% carbohydrate, 13% fat, 26%, protein, 2% fibre) for 12 weeks, 
followed by a structured food reintroduction (FR) (approximately 50% carbohydrate, 35% total fat, and 
15% protein) phase of 2–8 weeks, and then longer-term weight loss maintenance (WM). The programme 
allows some flexibility within defined ranges for duration of phases and maintenance diet composition, 
with support at regular review appointments with a dietitian or practice nurse (more frequently during 
the TDR and FR phases). Following weight loss, rescue packages of the formula diet may be provided if 
>2 kg weight is regained or diabetes returns. All oral antidiabetes and antihypertensive medications are 
ceased, on safety grounds, when participants begin the programme. These are reintroduced according to 
standard protocols under national clinical guidelines, where indicated by regular monitoring of blood 
glucose and blood pressure. Otherwise, participants in both groups continued to receive diabetes care 
under current National Health Service guidelines and standards.3,4 Further details of the DIRECT study 
design and intervention and 1-year clinical results have been published previously.1,2,5,6  
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Statistical analysis 
Mean resource use by category was calculated using all observations available in each case. Resource 
use data was incomplete for one participant in each group (< 1%) due to relocation. We assumed that the 
control group participant continued the oral antidiabetes/antihypertensive drugs throughout the period. 
The relocated intervention group participant attended only one intervention visit, so we assumed that 
their use of oral antidiabetes/antihypertensive drugs also continued. We assigned each participant zero 
other health-care contacts. Totals of mean 1-year costs were calculated for aggregated resource use for 
each participant: 95% CIs were based on 1000 non-parametric bootstrap iterations (samples with 
replacement from the observed data). All analyses were done according to the intention-to-treat principle 
and in STATA/MP 14.2 (StataCorp). 
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